Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary central nervous system lymphomas.

L M DeAngelis1

  • 1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021-6700, USA. deangell@mskcc.org

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas.

Journal of neuro-oncology·2017
Same author

OC-02 - Risk of arterial thromboembolism in patients with breast cancer.

Thrombosis research·2016
Same author

Multimodality imaging of primary CNS lymphoma in immunocompetent patients.

The British journal of radiology·2014
Same author

Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.

Leukemia·2011
Same author

Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2011
Same author

Leptomeningeal metastases in the MRI era.

Neurology·2010

High-dose methotrexate chemotherapy is the recommended initial treatment for primary central nervous system lymphoma (PCNSL). This approach is preferred over radiotherapy due to reduced neurotoxicity, especially in elderly patients.

Area of Science:

  • Oncology
  • Neurology
  • Cancer Treatment

Background:

  • Primary central nervous system lymphoma (PCNSL) is a rare brain tumor.
  • Historically, whole brain radiotherapy was the standard treatment.
  • Recent advancements highlight chemotherapy's growing role.

Purpose of the Study:

  • To evaluate the shift in treatment paradigms for PCNSL.
  • To emphasize the efficacy and safety of chemotherapy-based regimens.
  • To address the neurotoxicity concerns associated with radiotherapy.

Main Methods:

  • Review of current treatment strategies for PCNSL.
  • Analysis of data supporting chemotherapy as first-line treatment.
  • Consideration of patient age and neurotoxicity in treatment selection.

Related Experiment Videos

Main Results:

  • Chemotherapy, particularly high-dose methotrexate, is now the primary treatment for PCNSL.
  • Radiotherapy is increasingly omitted, especially in older patients, to mitigate neurotoxicity.
  • Emerging data support the effectiveness of chemotherapy-alone approaches.

Conclusions:

  • High-dose methotrexate-based chemotherapy should be the initial treatment for all PCNSL patients.
  • Avoiding or limiting radiotherapy can reduce late neurotoxicity, particularly in elderly individuals.
  • Ongoing research focuses on developing more effective chemotherapy regimens for PCNSL.